IRIS Accounts Production v26.2.0.496 09953150 director 1.2.25 31.1.26 31.1.26 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh099531502025-01-31099531502026-01-31099531502025-02-012026-01-31099531502024-01-31099531502024-02-012025-01-31099531502025-01-3109953150ns15:EnglandWales2025-02-012026-01-3109953150ns14:PoundSterling2025-02-012026-01-3109953150ns10:Director12025-02-012026-01-3109953150ns10:PrivateLimitedCompanyLtd2025-02-012026-01-3109953150ns10:SmallEntities2025-02-012026-01-3109953150ns10:AuditExemptWithAccountantsReport2025-02-012026-01-3109953150ns10:SmallCompaniesRegimeForDirectorsReport2025-02-012026-01-3109953150ns10:SmallCompaniesRegimeForAccounts2025-02-012026-01-3109953150ns10:FullAccounts2025-02-012026-01-3109953150ns10:OrdinaryShareClass12025-02-012026-01-3109953150ns10:RegisteredOffice2025-02-012026-01-3109953150ns5:CurrentFinancialInstruments2026-01-3109953150ns5:CurrentFinancialInstruments2025-01-3109953150ns5:ShareCapital2026-01-3109953150ns5:ShareCapital2025-01-3109953150ns5:FurtherSpecificReserve3ComponentTotalEquity2026-01-3109953150ns5:FurtherSpecificReserve3ComponentTotalEquity2025-01-3109953150ns5:LeaseholdImprovements2025-02-012026-01-3109953150ns5:PlantMachinery2025-02-012026-01-3109953150ns5:FurnitureFittings2025-02-012026-01-3109953150ns5:MotorVehicles2025-02-012026-01-3109953150ns5:ComputerEquipment2025-02-012026-01-3109953150ns5:LeaseholdImprovements2025-01-3109953150ns5:PlantMachinery2025-01-3109953150ns5:FurnitureFittings2025-01-3109953150ns5:LeaseholdImprovements2026-01-3109953150ns5:PlantMachinery2026-01-3109953150ns5:FurnitureFittings2026-01-3109953150ns5:MotorVehicles2025-01-3109953150ns5:ComputerEquipment2025-01-3109953150ns5:MotorVehicles2026-01-3109953150ns5:ComputerEquipment2026-01-3109953150ns5:AdditionsToInvestments2026-01-3109953150ns5:RevaluationsIncreaseDecreaseInInvestments2026-01-3109953150ns5:CostValuation2026-01-3109953150ns5:WithinOneYearns5:CurrentFinancialInstruments2026-01-3109953150ns5:WithinOneYearns5:CurrentFinancialInstruments2025-01-3109953150ns5:DeferredTaxation2025-01-3109953150ns5:DeferredTaxation2025-02-012026-01-3109953150ns5:DeferredTaxation2026-01-3109953150ns10:OrdinaryShareClass12026-01-31
REGISTERED NUMBER: 09953150 (England and Wales)














UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2026

FOR

CLAIRE DAVIES PHARMA CONSULTING LIMITED

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Report of the Accountants 8

CLAIRE DAVIES PHARMA CONSULTING LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 JANUARY 2026







DIRECTOR: Mrs C Milligan





REGISTERED OFFICE: 45 Queen Street
Deal
Kent
CT14 6EY





REGISTERED NUMBER: 09953150 (England and Wales)





ACCOUNTANTS: Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

BALANCE SHEET
31 JANUARY 2026

2026 2025
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 45,266 45,474
Investments 5 216,854 -
262,120 45,474

CURRENT ASSETS
Debtors 6 36,138 28,627
Cash at bank 408,483 352,201
444,621 380,828
CREDITORS
Amounts falling due within one year 7 113,875 91,580
NET CURRENT ASSETS 330,746 289,248
TOTAL ASSETS LESS CURRENT
LIABILITIES

592,866

334,722

PROVISIONS FOR LIABILITIES 8 18,910 7,628
NET ASSETS 573,956 327,094

CAPITAL AND RESERVES
Called up share capital 9 100 100
Fair value reserve 10 16,549 -
Retained earnings 557,307 326,994
SHAREHOLDERS' FUNDS 573,956 327,094

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2026 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

BALANCE SHEET - continued
31 JANUARY 2026


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 11 September 2026 and were signed by:





Mrs C Milligan - Director


CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026

1. STATUTORY INFORMATION

Claire Davies Pharma Consulting Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The Financial Statements are presented in round pounds sterling £.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover represents invoiced sales of services excluding value added tax. Revenue is recognised once the service has been completed.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - 10% on cost
Plant and machinery - 15% on reducing balance
Fixtures and fittings - 15% on reducing balance
Motor vehicles - 15% on reducing balance
Computer equipment - 33% on cost

Tangible fixed assets are tested for impairment annually.
It is the Company's policy to capitalise items with an estimated useful life in excess of two years, and for amounts in excess of £300.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
Pension Costs are represented by Company contributions to the director's personal pension scheme.

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2026

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2025 - 1 ) .

4. TANGIBLE FIXED ASSETS
Improvements Fixtures
to Plant and and
property machinery fittings
£    £    £   
COST
At 1 February 2025 55,270 499 6,297
Additions - - -
Disposals - - -
At 31 January 2026 55,270 499 6,297
DEPRECIATION
At 1 February 2025 49,999 188 4,846
Charge for year 5,271 47 217
Eliminated on disposal - - -
At 31 January 2026 55,270 235 5,063
NET BOOK VALUE
At 31 January 2026 - 264 1,234
At 31 January 2025 5,271 311 1,451

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 February 2025 56,090 3,131 121,287
Additions 42,419 916 43,335
Disposals (56,090 ) - (56,090 )
At 31 January 2026 42,419 4,047 108,532
DEPRECIATION
At 1 February 2025 19,645 1,135 75,813
Charge for year 6,007 1,023 12,565
Eliminated on disposal (25,112 ) - (25,112 )
At 31 January 2026 540 2,158 63,266
NET BOOK VALUE
At 31 January 2026 41,879 1,889 45,266
At 31 January 2025 36,445 1,996 45,474

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2026

5. FIXED ASSET INVESTMENTS
Other
investments
£   
COST OR VALUATION
Additions 194,040
Revaluations 22,814
At 31 January 2026 216,854
NET BOOK VALUE
At 31 January 2026 216,854

Cost or valuation at 31 January 2026 is represented by:

Other
investments
£   
Valuation in 2026 22,814
Cost 194,040
216,854

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Directors' current accounts - 1,304
Tax 329 329
Accrued income 35,809 26,994
36,138 28,627

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Tax 91,014 66,297
Social security and other taxes 185 163
VAT 20,755 24,199
Other creditors 7 6
Directors' current accounts 46 -
Accrued expenses 1,868 915
113,875 91,580

8. PROVISIONS FOR LIABILITIES
2026 2025
£    £   
Deferred tax 18,910 7,628

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2026

8. PROVISIONS FOR LIABILITIES - continued

Deferred
tax
£   
Balance at 1 February 2025 7,628
Provided during year 11,282
Balance at 31 January 2026 18,910

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2026 2025
value: £    £   
100 Ordinary 1.00 100 100

10. RESERVES
Fair
value
reserve
£   
Transfer to fair value reserve 16,549

At 31 January 2026 16,549

11. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

During the year the following Directors Loan Accounts subsisted;

Directors Loan Account
A member of key management personnel

During the year the Director advanced the Company £1,350 (2025: £NIL)

During the year the Company paid the Director £NIL (2025: £330)

As at the year end the Company owed the Director £46 (2024: £1,304 owed to the Company)

CLAIRE DAVIES PHARMA CONSULTING LIMITED

REPORT OF THE ACCOUNTANTS TO THE DIRECTOR OF
CLAIRE DAVIES PHARMA CONSULTING LIMITED

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 31 January 2026 set out on pages one to twelve and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.






Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY


Date: .............................................